Clinical Practice Session
Updates in Membranous Nephropathy: My Antigen Teacher
November 02, 2023 | 02:00 PM - 04:00 PM
Location: Room 204, Pennsylvania Convention Center
Session Description
It has been nearly 15 years since Beck et al. identified the M-type phospholipase A2 receptor (PLA2R) as the dominant target antigen in primary membranous nephropathy. Since then, a host of new antigens have been discovered. These antigens each have distinct clinicopathologic features and have taught us much about membranous nephropathy. This session focuses on the clinical and histopathologic features of these new antigens and how the practicing clinician can wield them.
Support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Define novel antigens as they pertain to the classification and nomenclature of membranous nephropathy
- Analyze NELL1's diagnostic implications regarding malignancy, autoimmune disease, and alternative and/or traditional indigenous medicine
- Discuss the mechanisms associated with autoantibody-mediated glomerular injury and the experimental systems available to study mechanisms
- Explain the clinical indications for kidney biopsy in PLA2R-associated membranous nephropathy and when it is acceptable to skip biopsy
Learning Pathway(s)
- Glomerular Diseases
- Pathology
Moderators
Presentations
- Antigens in Membranous Nephropathy: A Discussion of the Clinicopathologic Features and Nomenclature
02:00 PM - 02:30 PM
- Mechanisms of Injury in Glomerular Diseases
02:30 PM - 03:00 PM
- Updates on NELL-1-Associated Membranous Nephropathy: More Discoveries and More Questions
03:00 PM - 03:30 PM
- When to Skip the Biopsy in Membranous Nephropathy
03:30 PM - 04:00 PM